Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy
Breast Neoplasms
Conditions: official terms
Breast Neoplasms
Study Type
Study Phase
Phase 3
Study Design
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Sentinel lymph node procedure
Type: Procedure
Overall Status
STUDY AIM To decrease the number of breast cancer patients receiving over treatment of the axilla, in order to positively influence the axillary morbidity rate and quality of life.

PRIMARY OBJECTIVE To determine whether omitting the sentinel lymph node procedure is not inferior to the current axillary staging regimen in clinically node negative breast cancer patients undergoing breast conserving therapy, in terms of regional recurrence rate.

HYPOTHESIS The sentinel lymph node procedure can be safely omitted in clinically node negative breast cancer patients undergoing breast conserving therapy. This will lead to a decreased axillary morbidity rate, with a non-inferior regional recurrence-, distant-disease free- and overall survival rates.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Female

- Aged 18 years or older

- Pathologically confirmed invasive breast carcinoma

- A clinical T1-2 tumor

- Will be treated with lumpectomy and whole breast radiotherapy

- Clinically node negative status: no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or negative cyto-/histopathology)

- Written informed consent

Exclusion Criteria:

- Clinically node positive pre-operative

- Bilateral breast cancer

- Evidence of metastatic disease

- History of invasive breast cancer

- Previous treatment of the axilla with surgery or radiotherapy (except surgery for hidradenitis suppurativa or for other superficially located skin lesions, such as naevi)

- Pregnant or nursing

- Other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or unsuccessfully treated malignancies > 5 years before randomization

- Unable or unwilling to give informed consent
Maastricht University Medical Centre+
Maastricht, Limburg, Netherlands
Status: Recruiting
Contact: Marjolein L Smidt, MD, PhD - +31433877477
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands
Status: Not yet recruiting
Start Date
April 2015
Completion Date
April 2027
Maastricht University Medical Center
Maastricht University Medical Center
Record processing date processed this data on July 28, 2015 page